Global Health Technologies Coalition Global Health Technologies Coalition
  • Why R&D
  • R&D Facts
  • In Your State
  • Solutions
  • Breakthroughs Blog
  • News & Events
  • Resources
  • About Us
Stay Informed

Global health R&D delivers forColorado

Map
Colorado
Select a new state
Select a State
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois
Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana
Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island
South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

US government investment in global health R&D has delivered

$93.8 million
to Colorado research institutions
1,400+ new jobs
for Colorado
Colorado

Neglected diseases in Colorado

Chikungunya cases
Chikungunya cases
25
Dengue cases
Dengue cases
43
HIV diagnoses
HIV diagnoses
3491
Malaria cases
Malaria cases
199
Tuberculosis cases
Tuberculosis cases
668
West Nile cases
West Nile cases
1083
Zika cases
Zika cases
61
Colorado's top USG-funded global health R&D institutions

Colorado's top USG-funded global health R&D institutions

Colorado State University
$58.3 million
University of Colorado at Denver
$27.2 million
University of Colorado at Boulder
$5.8 million
Precision Photonics Corporation (now part of IDEX Corporation)
$1.4 million
Colorado School of Mines
$1 million
Keystone Symposia on Molecular and Cellular Biology
$88 thousand
Colorado industry in global health R&D

Colorado industry in global health R&D

AstraZeneca
Location(s): Boulder
Endolytics
Location(s): Fort Collins
IDEX Corporation
Location(s): Denver
Mbio
Location(s): Boulder
Novartis
Location(s): Broomfield
Sandoz
Location(s): Broomfield
SomaLogic
Location(s): Boulder

Colorado's top areas of global health R&D by USG funding

11.5%
HIV/AIDS
5.5%
Malaria
48.3%
Tuberculosis
2.7%
Diarrheal diseases
7.8%
Salmonella infections
19.7%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
Leprosy
4.5%
Other
Bacterial pneumonia & meningitis
Non-allocable
Global health R&D at work in Colorado
Global health R&D at work in Colorado

University of Colorado School of Medicine researchers discovered that a process that protects the body from autoimmune disease also blocks the production of antibodies against HIV-1, the most common cause of AIDS. The immune system normally suppresses these antibodies to keep them from targeting healthy tissues; the question now is whether temporarily halting this mechanism would allow generation of antibodies capable of neutralizing HIV-1 without harm to patients. The findings could help scientists develop a vaccine.

Download PDF
Map
Select a new state
Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Patrick McKern
Close
advancing innovation to save lives

© 2009–2021, PATH, as secretariat of the Global Health Technologies Coalition.

  • Stay Informed
  • Join Us
  • Contact Us
  • GHTC Member Log In